{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-027295","form_type":"8-K/A","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.394094+00:00","generated_at":"2026-06-23T06:34:17.270331+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Lineage Cell corrects CEO salary to $609k in amended employment agreements","bullets":["Corrects CEO Brian Culley's base annual salary from $690,000 to $609,000.","Corrects cash severance payment method: installments for termination without cause/good reason, lump sum only within change-of-control window.","Other terms unchanged: Samuel salary $394,800, Hogge $366,800; bonus targets 55%, 40%, 35% respectively.","Board adopted Executive Performance Incentive Bonus Plan (as originally disclosed)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-027295","json":"https://secwatch.observer/filing/0001493152-22-027295.json","markdown":"https://secwatch.observer/filing/0001493152-22-027295.md","text":"https://secwatch.observer/filing/0001493152-22-027295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222027295/0001493152-22-027295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222027295/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:34:17.270331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}